Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection
Status:
Unknown status
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
1. Evaluate the safety, tolerability, and virologic activity of escalating single (and
multiple) doses of XTL6865, a mixture (1:1) of two human monoclonal antibodies
(HCV-AbXTL68 and HCV-AbXTL65), in patients with chronic hepatitis C virus infection.
2. Assess the pharmacokinetics of XTL6865 in the presence and absence of viral infection.